$ZLAB News

Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached

Zai Lab Limited 2026 Q1 - Results - Earnings Call Presentation

The FDA Grants Fast Track Designation To Zai Lab's Zocilurtatug Pelitecan (Zoci, formerly ZL-1310) for Extrapulmonary Neuroendocrine Carcinomas Following Progression After Standard First-Line Therapy

Citigroup Maintains Buy on Zai Lab, Lowers Price Target to $44

Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript

Zai Lab Q1 EPS $(0.46) Beats $(0.54) Estimate, Sales $99.611M Miss $108.450M Estimate

Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - Slideshow

Zai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases Transcript

Reported Earlier, Zai Lab Announced New Data From A Preclinical Study Of ZL-1503, Demonstrating That The Company's Internally Developed IL-13/IL-31Rα Bispecific Antibody May Lead To Sustained Suppression Of Intense Pruritus And Inflammation Caused By Atopic Diseases

Zai Lab Announces Clinical Data Indicating Zoci, DLL3-Targeting ADC, Provides Rapid And Robust Intracranial Responses In Patients With Previously Treated ES-SCLC And Brain Metastases And Other NECs

Boehringer Ingelheim, Zai Lab Collaborate Over Dual DLL3-Targeting Combination To Assess Safety, Tolerability Of Combining Obrixtamig, Boehringer Ingelheim's DLL3/CD3 T-Cell Engager

Zai Lab shares are trading higher after a global clinical trial collaboration to explore the clinical potential of its DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen's IMDELLTRA.

JP Morgan Maintains Overweight on Zai Lab, Lowers Price Target to $32

Zai Lab To Present Investigational Oncology Therapies To Be Presented Across Four Posters At American Association For Cancer Research Annual Meeting 2026

Zai Lab Limited 2025 Q4 - Results - Earnings Call Presentation

Cantor Fitzgerald Maintains Overweight on Zai Lab, Lowers Price Target to $37

Zai Lab Limited (ZLAB) Q4 2025 Earnings Call Transcript

CORRECTION: Zai Lab Q4 EPADS $(0.46) Misses $(0.05) Estimate, Sales $127.597M Beat $124.472M Estimate

Zai Lab: Q4 Earnings Insights

Zai Lab Q4 Earnings Summary & Key Takeaways